HomeCompareNVTA vs SPHD

NVTA vs SPHD: Dividend Comparison 2026

NVTA yields 10526.32% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVTA wins by $91421458538285344.00M in total portfolio value
10 years
NVTA
NVTA
● Live price
10526.32%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$91421458538285344.00M
Annual income
$89,744,322,218,307,970,000,000.00
Full NVTA calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — NVTA vs SPHD

📍 NVTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVTASPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVTA + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVTA pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVTA
Annual income on $10K today (after 15% tax)
$894,736.84/yr
After 10yr DRIP, annual income (after tax)
$76,282,673,885,561,770,000,000.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, NVTA beats the other by $76,282,673,885,561,770,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVTA + SPHD for your $10,000?

NVTA: 50%SPHD: 50%
100% SPHD50/50100% NVTA
Portfolio after 10yr
$45710729269142672.00M
Annual income
$44,872,161,109,153,986,000,000.00/yr
Blended yield
98.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SPHD right now

NVTA
Analyst Ratings
4
Buy
6
Hold
5
Sell
Consensus: Hold
Price Target
$9.75
+51215.8% upside vs current
Range: $2.25 — $17.00
Altman Z
-23.1
Piotroski
4/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVTA buys
0
SPHD buys
0
No recent congressional trades found for NVTA or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVTASPHD
Forward yield10526.32%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$91421458538285344.00M$26.5K
Annual income after 10y$89,744,322,218,307,970,000,000.00$571.32
Total dividends collected$91309952364754128.00M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NVTA vs SPHD ($10,000, DRIP)

YearNVTA PortfolioNVTA Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$1,063,332$1,052,631.58$11,133$432.85+$1.05MNVTA
2$105,744,905$104,607,140.08$12,363$450.36+$105.73MNVTA
3$9,835,430,757$9,722,283,708.79$13,695$467.39+$9835.42MNVTA
4$855,644,041,989$845,120,131,078.84$15,138$483.90+$855644.03MNVTA
5$69,627,827,846,009$68,712,288,721,080.95$16,697$499.88+$69627827.83MNVTA
6$5,300,152,192,813,391$5,225,650,417,018,161.00$18,382$515.31+$5300152192.80MNVTA
7$377,430,657,448,967,200$371,759,494,602,656,830.00$20,198$530.17+$377430657448.95MNVTA
8$25,145,413,383,015,215,000$24,741,562,579,544,820,000.00$22,157$544.46+$25145413383015.20MNVTA
9$1,567,417,121,474,185,500,000$1,540,511,529,154,359,300,000.00$24,266$558.18+$1567417121474185.50MNVTA
10$91,421,458,538,285,340,000,000$89,744,322,218,307,970,000,000.00$26,536$571.32+$91421458538285344.00MNVTA

NVTA vs SPHD: Complete Analysis 2026

NVTAStock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Full NVTA Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this NVTA vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVTA vs SCHDNVTA vs JEPINVTA vs ONVTA vs KONVTA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.